MSB heads into its full-year results today with short sellers retreating at the margin — yet the positioning backdrop remains decisively bearish.
Short interest has fallen steadily over the past month, dropping roughly 7% to 7.5% of the free float. That is still a meaningful short position for an ASX-listed biotech. Days to cover sit near 29, implying shorts cannot exit quickly without moving the stock. The retreat looks tactical rather than capitulatory — bears are trimming, not leaving.
The borrow market tells a more nuanced story. Availability has loosened slightly over the past week, rising to around 50% from a tighter reading near 44% in mid-August. That loosening follows a period in which cost to borrow climbed roughly 44% over the past month to just over 2%, suggesting demand for short exposure picked up materially through July and early August before easing into the print. The 52-week history is stark: availability once dropped to near zero — every share in the lending pool fully lent — and is only now back to a middling level. The borrow market is tight relative to that historical range, but not stressed.
The ORTEX short score reinforces the bear-heavy framing. At 77.9, it places MSB in the bottom tier of the universe on short-score rank — only the 4th percentile — meaning few stocks carry a more bearish short-positioning signal. The score has been declining modestly from around 78.6 two weeks ago, consistent with the gentle short-covering trend. On days to cover, the stock ranks in just the 2nd percentile, flagging how illiquid the exit path is for short sellers relative to daily volume.
The fundamental debate is genuinely lopsided heading into the print. The growth case is compelling on paper: forward EPS estimates have been rising sharply, and the one-year sales increase has been exceptional for a biotech at this stage. The 12-month forward EPS year-on-year improvement ranks in the 97th percentile across the ORTEX universe — a standout. But profitability remains elusive. The Piotroski F-score of 3 and negative return on assets confirm the business has not yet converted revenue momentum into earnings. A PE near 9.9x and price-to-book of 3.9x are not obviously cheap for a pre-profit biotech with this level of short interest. The most recent analyst consensus target of AUD 3.93 implies meaningful upside from the current AUD 2.36, though that data is now over three weeks old and should be treated with some caution. The CEO, Silviu Itescu, added over 10 million shares as recently as July, a notable sign of insider confidence at current levels.
The annual results will test whether MSB's revenue trajectory is durable enough to justify the bull case on forward earnings — and whether the still-elevated short base has reason to cover in size or dig in further.
See the live data behind this article on ORTEX.
Open MSB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
